MetalloBio

MetalloBio is a Sheffield-based biotechnology company developing a new class of antimicrobial compounds to address the global challenge of multi-drug resistant (MDR) bacteria. The company utilizes a proprietary inorganic chemistry platform to create ruthenium-based complexes that feature unique, pluri-modal mechanisms of action designed to minimize the emergence of resistance. Its lead pharmaceutical candidate, KLS-116, is being developed for systemic treatment of complicated respiratory infections, including those associated with cystic fibrosis and hospital-acquired pneumonia. Additionally, MetalloBio develops antimicrobial coatings (Series 2) for medical devices such as catheters and orthopedic implants to prevent healthcare-associated infections. The company's business model focuses on advancing candidates through Phase 2 clinical trials before establishing licensing partnerships for late-stage development.